<DOC>
	<DOCNO>NCT00716144</DOCNO>
	<brief_summary>Eligible subject randomly assign one three dose regimens oral R115866 placebo treatment severe plaque psoriasis 12 twelve week . The safety efficacy R115866 evaluate treatment period 8-week post treatment follow-up period .</brief_summary>
	<brief_title>Dose Ranging Study Safety Efficacy R115966 Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>R 115866</mesh_term>
	<criteria>Plaque Psoriasis PASI great equal 10 Male female NOT childbearing potential ( i.e. , post menopausal great 12 month complete hysterectomy ) ; Spontaneously improve rapidly deteriorate plaque psoriasis Guttate , pustular , erythrodermic , nonplaque form psoriasis Subject treatment heart disorder history cardiovascular disease ( exclude effectively control hypertension ) Any acute psychiatric condition , include increase risk suicide attempt , base medical psychiatric history Previous use psoriasis vaccine participate investigational study psoriasis vaccine Previous use systemic immunomodulatory therapy know affect psoriasis typically decrease immune cell population Previous use systemic immunomodulatory therapy know affect psoriasis NOT typically decrease immune cell population Previous use phototherapy ( include laser ) , photochemotherapy , systemic psoriasis therapy ( systemic corticosteroid , methotrexate , retinoids , cyclosporine ) within previous four week Pregnant nursing mother Significant coexisting hepatic , renal , bone marrow disease , hyperlipidemia , chronic pancreatitis , osteoporosis , cancer ( except nonmelanoma skin cancer ) , positive test human immunodeficiency virus ( HIV ) , history indicate adrenal cortex dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>